SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6 K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
EDAP TMS S.A. Files
Press Releases issued in
September 2002 and
October 2002
EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin
France
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F .........X........ Form 40-F.................
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ............ No .....X.....
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date :
EDAP TMS S.A.
S/PHILIPPE CHAUVEAU
PHILIPPE CHAUVEAU
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
EDAP TMS S.A. ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS
Vaulx-en-Velin, France, October 2, 2002-- EDAP TMS S.A. (Nasdaq: EDAP), a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today announced the appointment of Mr. Pierre Beysson to the Board of Directors. Mr. Beysson replaces Mr. Christian Baillet who recently resigned.
Mr. Pierre Beysson is the current chief financial officer of Compagnie des Wagons-Lits, the on-board train service division of Accor, a French multinational hotel and business service group. Previously, he served in a number of senior financial positions with global companies including Nixdorf Computers, Trane, AM International and FMC. Mr. Beysson is a CPA and holds an MBA degree from the Harvard Business School.
The company also announced that Mr. Christian Baillet, the managing director and a board member of Quilvest Group, has resigned from the EDAP TMS S.A. board after nine years of service.
"Pierre brings a wealth of knowledge and experience to EDAP's board. He has a strong financial background, which will serve him well as the chair of the audit committee, and will help him to contribute creatively to our future direction and growth," said Philippe Chauveau, Chairman and Chief Executive Officer of EDAP TMS S.A. Mr. Chauveau extended special appreciation to Mr. Baillet commenting, "Christian has played a key role in EDAP's strategic direction and we will greatly miss his counsel."
EDAP TMS S.A.
is the global leader in the development, production, marketing and distribution
of a portfolio of minimally invasive medical devices primarily for the treatment
of urological diseases. The Company currently produces and markets devices
for the minimally invasive treatment of localized prostate cancer, using High
Intensity Focused Ultrasound (HIFU) and the treatment of urinary tract stones
using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company also produces
and markets in Japan and Italy devices for the non-surgical treatment of benign
Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The Company
is also developing HIFU for the treatment of certain other types of tumors.
For more information, in the U.S., contact EDAP Technomed Inc., the Company's
U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950.
EDAP TMS S.A. APPOINTS HUGUES DE BANTEL AS PRESIDENT OF TECHNOMED MEDICAL SYSTEMS
Vaulx-en-Velin, France, September 17, 2002-- EDAP TMS S.A. (Nasdaq: EDAP). EDAP TMS today announced the appointment of Hugues de Bantel as president of Technomed Medical Systems S.A., based in Lyon, France. On July 30, 2002, the Company announced that its new corporate structure would be organized into two divisions: the High Intensity Focused Ultrasound ("HIFU") division, EDAP S.A., and the urology devices and services division, Technomed Medical Systems S.A. At that time Antoine Tetard, previously COO of EDAP TMS S.A., was appointed president of EDAP S.A
Mr. de Bantel joined the company in 1996, and has held various sales and management positions in the Company's Asia-Pacific region, most notably creating the Company's subsidiary in Malaysia. Recently, Mr. de Bantel served as president of the Company's subsidiary in Japan.
Commenting on the appointment, Chairman and CEO Philippe Chauveau said, "I am very pleased that we were able to appoint two proven leaders, with many years of management experience in EDAP, as the presidents of our two divisions."
Separately, the Company appointed Shuzo Nagahisa, to replace Mr. de Bantel, as president of the Company's subsidiary in Japan. Mr. Nagahisa, a Chemical Engineer, progressed through various general management, sales, marketing and quality positions over his 25 year career, including 14 years at G.E. Plastics, Japan. Marc Abela, Vice-President & Sales Director, of EDAP's Japanese subsidiary will report to Mr. Nagahisa.
Reporting to Mr. de Bantel are the Company's subsidiaries which are headed by: Young Hwan Park, president of the Korean susidiary; Marc Oczachowski, managing director of the Malaysian subsidiary; and Timothy Heyer, general manager of the USA subsidiary. As part of the new corporate structure, director of manufacturing Philippe Chapuis, director of customer service/support Vincent Pasquier, and director of quality and regulatory affairs Philippe Scuiller, will also report to Mr. de Bantel.
EDAP
TMS S.A. is the global leader in the development, production, marketing and
distribution of a portfolio of minimally invasive medical devices primarily
for the treatment of urological diseases. The Company currently produces and
markets devices for the minimally invasive treatment of localized prostate cancer,
using High Intensity Focused Ultrasound (HIFU) and the treatment of urinary
tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company
also produces and markets in Japan and Italy devices for the non-surgical treatment
of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The
Company is also developing HIFU for the treatment of certain other types of
tumors. For more information, in the U.S., contact EDAP Technomed Inc., the
Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950.